Media Doctor Canada
Follow us on Twitter








"Popular diabetes drugs may double heart risks"

Globe and Mail

Source: Globe and Mail

Published: 27 Jul 2022

Category: Harm Stories

Rating: (4½ stars)

what they said (Hover the mouse cursor over underlined words for more info)

A class of drugs commonly used to treat diabetes doubles the risk of heart failure, according to a new study.

The findings, published in today's edition of the journal Diabetes Care, are sure to increase the scrutiny given to thiazolinediones, or TZDs, which are among the world's bestselling drugs.

Earlier this year, research showed that TZD sold under the brand name Avandia sharply increased the risk of heart attack and death from cardiovascular causes. The drug's manufacturer, GlaxoSmithKline, has rejected that research by presenting data showing Avandia is no more dangerous than other oral diabetes drugs....

The original article can be found at:

how did it rate? (more information)

Criteria Rating
Total Score 6 of 7
Novelty of harm Satisfactory (?)
Benefit to harm ratio Satisfactory (?)
Evidence Satisfactory (?)
Quantification of Harms Satisfactory (?)
Number of people affected by harm Satisfactory (?)
Stratification of patients with regard to harm Satisfactory (?)
Sources of Information Not Satisfactory (?)
Treatment options Not Applicable
Relies on Press Release Not Applicable

what we said (Hover the mouse cursor over underlined words for more info)

The study that this article is reporting on only looked at one particular drug and was not a comparison of the harms of two or more products. Therefore, any mention of the harms of this particular product relative to other oral hypoglycemics would not be relevant.
Overall this is a good summary of recent findings regarding the safety of the most popular (and expensive) oral drugs for diabetes. It should serve as a reminder that newer is not necessarily better.

public forum

There are currently no comments on this article.

voice your opinion in the forum

  • All comments and feedback submitted to Media Doctor are subject to editorial approval before being made viewable by the public. It may take up to a week for your comments to be approved. Additionally, no response will be given to questions posed in public comments. Media Doctor does not provide medical advice, or answers to medical questions posed by the public.
  • If you provide your email address it will not be displayed to the general public.
  • Comments may be edited by Media Doctor to remove defamatory or sensitive statements, and brand names.
  • Required fields are marked with an asterisk (*).
Name: *
Comments: *
Copyright © Media Doctor Canada